RhumbLine Advisers’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13M | Sell |
173,440
-1,947
| -1% | -$154K | 0.01% | 931 |
|
|
2025
Q4 | $13.9M | Sell |
175,387
-6,674
| -4% | -$503K | 0.01% | 912 |
|
|
2025
Q3 | $11.9M | Buy |
182,061
+462
| +0.3% | +$22.6K | 0.01% | 996 |
|
|
2025
Q2 | $7.17M | Sell |
181,599
-6,617
| -4% | -$217K | 0.01% | 1221 |
|
|
2025
Q1 | $5.68M | Sell |
188,216
-3,677
| -2% | -$120K | 0.01% | 1291 |
|
|
2024
Q4 | $6.71M | Sell |
191,893
-5,049
| -3% | -$189K | 0.01% | 1266 |
|
|
2024
Q3 | $7.89M | Buy |
196,942
+18,853
| +11% | +$877K | 0.01% | 1180 |
|
|
2024
Q2 | $8.49M | Sell |
178,089
-1,330
| -0.7% | -$54.5K | 0.01% | 1110 |
|
|
2024
Q1 | $7.78M | Sell |
179,419
-19,997
| -10% | -$953K | 0.01% | 1173 |
|
|
2023
Q4 | $10.1M | Buy |
199,416
+1,956
| +1% | +$93.7K | 0.01% | 1054 |
|
|
2023
Q3 | $8.96M | Buy |
197,460
+127
| +0.1% | +$5.24K | 0.01% | 1038 |
|
|
2023
Q2 | $8.1M | Buy |
197,333
+20,648
| +12% | +$793K | 0.01% | 1119 |
|
|
2023
Q1 | $6.32M | Buy |
176,685
+11,522
| +7% | +$433K | 0.01% | 1187 |
|
|
2022
Q4 | $6.24M | Buy |
165,163
+9,449
| +6% | +$397K | 0.01% | 1158 |
|
|
2022
Q3 | $6.89M | Buy |
155,714
+1,212
| +0.8% | +$51.1K | 0.01% | 1080 |
|
|
2022
Q2 | $5.72M | Buy |
154,502
+20,942
| +16% | +$790K | 0.01% | 1176 |
|
|
2022
Q1 | $4.95M | Sell |
133,560
-6,189
| -4% | -$203K | 0.01% | 1318 |
|
|
2021
Q4 | $4.25M | Buy |
139,749
+1,386
| +1% | +$43.6K | 0.01% | 1451 |
|
|
2021
Q3 | $4.64M | Sell |
138,363
-1,222
| -0.9% | -$46K | 0.01% | 1402 |
|
|
2021
Q2 | $5.57M | Sell |
139,585
-4,821
| -3% | -$189K | 0.01% | 1368 |
|
|
2021
Q1 | $6.49M | Sell |
144,406
-7,405
| -5% | -$413K | 0.01% | 1255 |
|
|
2020
Q4 | $8.58M | Sell |
151,811
-2,634
| -2% | -$131K | 0.01% | 1024 |
|
|
2020
Q3 | $7.33M | Sell |
154,445
-5,360
| -3% | -$298K | 0.01% | 933 |
|
|
2020
Q2 | $9.42M | Buy |
159,805
+20,354
| +15% | +$1.13M | 0.02% | 805 |
|
|
2020
Q1 | $6.59M | Sell |
139,451
-1,833
| -1% | -$102K | 0.01% | 868 |
|
|
2019
Q4 | $8.54M | Buy |
141,284
+3,423
| +2% | +$204K | 0.01% | 933 |
|
|
2019
Q3 | $8.26M | Sell |
137,861
-822
| -0.6% | -$53.6K | 0.02% | 888 |
|
|
2019
Q2 | $8.91M | Sell |
138,683
-2,300
| -2% | -$163K | 0.02% | 839 |
|
|
2019
Q1 | $11.4M | Sell |
140,983
-793
| -0.6% | -$51.2K | 0.02% | 700 |
|
|
2018
Q4 | $7.66M | Sell |
141,776
-5,337
| -4% | -$272K | 0.02% | 853 |
|
|
2018
Q3 | $7.59M | Sell |
147,113
-2,733
| -2% | -$128K | 0.01% | 832 |
|
|
2018
Q2 | $6.24M | Buy |
149,846
+2,512
| +2% | +$111K | 0.01% | 952 |
|
|
2018
Q1 | $6.49M | Sell |
147,334
-4,441
| -3% | -$226K | 0.01% | 884 |
|
|
2017
Q4 | $7.63M | Sell |
151,775
-2,325
| -2% | -$127K | 0.02% | 823 |
|
|
2017
Q3 | $7.81M | Sell |
154,100
-3,984
| -3% | -$209K | 0.02% | 790 |
|
|
2017
Q2 | $8.04M | Sell |
158,084
-2,114
| -1% | -$98.4K | 0.02% | 736 |
|
|
2017
Q1 | $6.44M | Buy |
160,198
+5,738
| +4% | +$258K | 0.02% | 861 |
|
|
2016
Q4 | $7.39M | Buy |
154,460
+11,319
| +8% | +$448K | 0.02% | 759 |
|
|
2016
Q3 | $5.25M | Buy |
143,141
+6,594
| +5% | +$206K | 0.01% | 856 |
|
|
2016
Q2 | $3.18M | Buy |
136,547
+5,504
| +4% | +$178K | 0.01% | 1068 |
|
|
2016
Q1 | $5.31M | Buy |
131,043
+90
| +0.1% | +$3.66K | 0.02% | 808 |
|
|
2015
Q4 | $8.11M | Buy |
130,953
+2,370
| +2% | +$128K | 0.03% | 597 |
|
|
2015
Q3 | $5.2M | Buy |
128,583
+2,778
| +2% | +$144K | 0.02% | 790 |
|
|
2015
Q2 | $7.24M | Sell |
125,805
-4,956
| -4% | -$315K | 0.02% | 658 |
|
|
2015
Q1 | $8.33M | Buy |
130,761
+19,050
| +17% | +$1.29M | 0.02% | 592 |
|
|
2014
Q4 | $6.9M | Sell |
111,711
-3,237
| -3% | -$160K | 0.02% | 643 |
|
|
2014
Q3 | $4.46M | Sell |
114,948
-1,925
| -2% | -$68.2K | 0.01% | 831 |
|
|
2014
Q2 | $4.03M | Sell |
116,873
-2,722
| -2% | -$85.7K | 0.01% | 911 |
|
|
2014
Q1 | $5.17M | Sell |
119,595
-4,960
| -4% | -$240K | 0.02% | 802 |
|
|
2013
Q4 | $4.96M | Buy |
124,555
+6,190
| +5% | +$221K | 0.01% | 823 |
|
|
2013
Q3 | $4.44M | Sell |
118,365
-403
| -0.3% | -$12K | 0.01% | 864 |
|
|
2013
Q2 | $3.19M | Buy |
+118,768
| New | +$2.53M | 0.01% | 1021 |
|
Other funds holding IONS
VPM
VCM
RhumbLine Advisers's IONS Position: Q1 2026 in Review
RhumbLine Advisers reduced its Ionis Pharmaceuticals (IONS) stake by 1.1% in Q1 2026, selling an estimated $154K and leaving 173,440 shares worth $13M. The position accounts for 0.01% of the portfolio, ranked #931.
RhumbLine Advisers first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.9M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- RhumbLine Advisers held 173,440 shares of Ionis Pharmaceuticals worth $13M as of Q1 2026.
- RhumbLine Advisers sold 1,947 Ionis Pharmaceuticals shares in Q1 2026, an estimated $154K.
- Ionis Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #931 holding.
- RhumbLine Advisers first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- RhumbLine Advisers's Ionis Pharmaceuticals position peaked at $13.9M in Q4 2025.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.